Introduction: Bevacizumab has demonstrated activity in glioblastoma (GBM), but
| INTRODUCTION
Glioblastoma (GBM) has one of the highest mortality rates of any cancer. Following maximal surgical resection, radiation with concurrent and adjuvant temozolomide is standard. 1 However, tumor progression inevitably occurs and second-line treatment options are limited, with median survival ranging from 3 to 9 months. 2, 3 Vascular proliferation is one of the pathological hallmarks of glioblastoma, which expresses high levels of the Vascular Endothelial Growth Factor Receptor (VEGFR). [4] [5] [6] In progressive GBM the monoclonal antibody bevacizumab, which targets VEGFR, results in reduced tumor vascularity and vascular permeability. 7 While there is some evidence patients appear to be living longer on average since its approval by the Federal Drug Administration (FDA) in the United States in 2009, 8 bevacizumab has not yet shown an overall survival (OS) benefit in randomized phase III trials, and is not approved by the European Medicines Agency (EMA). An important benefit of bevacizumab in progressive GBM might be symptom control, since it can reduce cerebral edema with a resultant decrease in corticosteroid use. 9, 10 10 mg/kg every 2 weeks (q2/52) bevacizumab was the standard dose used in early and subsequent trials. 9, [11] [12] [13] However, it has since been suggested that a lower dose might offer similar benefits but with less toxicities and lower financial cost. [14] [15] [16] Hence, the optimal bevacizumab dose is debated and has led to variable practice between Neuro-Oncologists. In our institution, patients are randomly assigned on a rota system to one of three NeuroOncologists, who use different doses of bevacizumab in their practices. In this retrospective study we examined whether bevacizumab dose had an impact on patient outcomes, analysed for potential predictive factors and performed a comparative cost analysis.
| METHODS
This was a retrospective single-institution study in the national neuro-oncology tertiary referral centre in Ireland.
Patients who received at least one dose of bevacizumab for progressive GBM between January 1, 2010 and January 1, 2017 were identified from the prospectively maintained patient database. All patients had received first-line standard radiotherapy with concurrent and adjuvant temozolomide and were followed by a standard protocol prior to diagnosis of progression and commencing bevacizumab. Patients with de novo WHO Grade IV GBM only were included, while those with a history of WHO Grade II or III tumors who later progressed to GBM were excluded. As this study reflected everyday practice, patients were included irrespective of baseline performance status. 
| Study procedures

| Dose-levels
As this was a retrospective study, dose-levels were pre-defined by the different practices of the treating Neuro-oncologists in our institution. No patient factors determined to which neuro-oncologist the patients were randomly assigned, and therefore did not impact on the bevacizumab schedule received. For the purposes of this analysis, patients were grouped into standard-dose (10 mg/kg q2/52 or 15 mg/kg q3/52) or reduced-dose (5 mg/kg q2/52 or 7.5 mg/kg q3/52) bevacizumab. No patients changed dose schedule between the standard-dose and reduced-dose groups.
| Endpoints
The primary endpoint was overall survival, measured from the date of first administered bevacizumab dose until death from any cause, among the standard-dose and reduced-dose bevacizumab cohorts. Secondary endpoints included age at diagnosis, time from diagnosis to bevacizumab start, gender, MGMT methylation, baseline PS and steroid use, and a comparative cost analysis. No attempt was made to retrospectively determine progression free survival (PFS) as pseudoprogression and radiation necrosis would have confounded accurate progression assessment. 17, 18 Adverse events (AE's) such as hypertension, proteinuria, or thromboembolic events were not assessed due to the unreliable nature of retrospective documentation and the likelihood that patients had AE's treated elsewhere, eg hypertension with their primary care physician, given the tertiary care model in Ireland, thus making analyses inaccurate.
| Exploratory analyses
Clinical status (stable/improved/worse vs previous visit), steroid use (yes/no & stable/increased/reduced dose vs previous visit), clinical benefit (any "stable" or "improved" clinical visit), steroid benefit (any reduction in steroid dose or stable steroid dose as the best response) and best clinical response (stable vs improved vs worse) were assessed by chart review and analysed as exploratory endpoints. Patients were subdivided into three groups to assess whether age at diagnosis impacted on OS; patients aged <50 years, patients aged between 50 and 65 years (ie 50 years ≤ GBM diagnosis ≤65 years), and patients aged >65 years at the time of their GBM diagnosis. Similarly, patients were subdivided into three groups (<12 months, 12-18 months and >18 months after histological GBM diagnosis) to assess whether this impacted OS.
| Statistical analysis
Standard descriptive statistics were employed to describe the entire study population, and both the standard-and reduced-dose patient groups. To ensure comparability, Fisher or chi-squared tests for categorical data and t-test for continuous data were performed to assess for significant differences between the groups. A multivariate analysis for OS was planned if more than one univariate analysis reached statistical significance. Patients were censored at the time of death, the study endpoint (January 1, 2017) if still alive, or at their last confirmed hospital visit if lost to follow-up and no definite date of death could be obtained. Survival curves were estimated by the Kaplan-Meier method and compared using the log rank test (univariate analyses). OS rates at the predefined cut-off points of 6-, 12-, and 24-months were also compared with published data.
| Cost analysis
Costs associated with bevacizumab administration at both standard-dose and reduced-dose were evaluated for the entire study period. Costs of bevacizumab were calculated based on the mean bevacizumab dose received by each patient across their treatment period. Bevacizumab was priced based on current costs in January 2019 in Ireland; €470.69 ($531.30) per 100mg vial, €1783.78 ($2013.48) per 400 mg vial. The combination of 400 mg and 100 mg vials which enabled minimal wastage was used to estimate costs in all cases. For example, for bevacizumab 700 mg, one 400 mg vial and three 100 mg vials were used, rather than two 400 mg vials.
| RESULTS
| Patient demographics
One hundred and eighteen (N = 118) patients received bevacizumab for progressive GBM during the study timeframe. Median age at diagnosis was 60 (Range: 18-85) years with a male predominance (N = 77, 65.2%). Patients were predominantly Caucasian. The median time from histological GBM diagnosis to first bevacizumab treatment was 12.7 months (Range: 3.6-54.3 months). 24 (20%) patients had a second surgery, 5 of which were for maximal safe resection after an initial biopsy-only procedure, meaning 19 (16%) patients underwent re-resection or debulking of their tumors prior to starting bevacizumab. MGMT Methylation status was assessable in 86/118 patients, 72.9% of the entire population. IDH-1 mutation status was available in 90/118 patients (76.3%). There were no 1p/19q co-deleted patients in the study population. ATRX mutation status was available in 47/118 patients (40%, Table 1 ). In total, 1,127 bevacizumab doses were administered over the study period (Median: 7, Range: 1-44 per patient). Clinical data from chart review were available in 75/118 (64%) patients. Of these, 53/75 (71%) patients had available data on baseline steroid use with 34/53 (64%) taking steroids at baseline. Evaluable information on steroid dose was available from 607 treatment visits and on clinical status was available from 716 treatment visits (Table S1 ).
69 (59%) patients received standard-dose bevacizumab and 49 (41%) patients received reduced-dose bevacizumab. Both groups were similar with regards to age range, gender, time from diagnosis, MGMT methylation status %, time from diagnosis to bevacizumab start, IDH mutation status and ATRX alteration status (Table 1 and Tables S1,S2 ). 568 standard-dose bevacizumab cycles were administered (Median: 6, Range: 1-36) while 549 reduced-dose bevacizumab cycles were administered (Median: 8, Range: 1-44; Table S1 ). 
| Overall survival, entire population
| Overall survival by dose group
Median OS was similar in patients who received standarddose (5.97 months) and reduced-dose (5.7 months) bevacizumab (Δ 0.27 months, HR: 1.11, P-value: .584, Figure 1 ). Similar OS was seen at 6-months (47.7% vs 47.2%), 12-months (23.6% vs 17.5%) and 18-months (12% vs 10%) in both bevacizumab cohorts. Univariate analysis showed no impact of patient and tumor characteristics on median OS (Table S2) . Table S2 ).
| Clinical status and steroid use by dose group
Higher proportions of "stable" (82.3% vs 74.5%) and lower rates of "worse" (11.9% vs 18.1%) clinical status were seen in the reduced dose bevacizumab group vs the standard dose bevacizumab group, respectively, while the number of visits where the patients clinical status "improved" was low in both groups (7.4% vs 5.8%, Figure S1 ). Steroids were "decreased" more commonly in the standard vs reduced-dose cohorts (16.8% vs 11.2%), but also "increased" more commonly (14.4% vs 10.4%, Figure S2 ).
Best clinical response assessment identified 41.4% of patients as having an "improved" clinical status between any two treatment visits while on bevacizumab. 48.6% of patients had "stable" best clinical response while 10% of patients were "worse" as their best clinical response ( Figure S3 ). Numerical but not statistical differences were seen between the standard and reduced-dose cohorts (Table S3) .
Clinical Benefit was seen in 91% of the entire population (63/69 evaluable patients). Rates were slightly higher in T A B L E 1 Baseline patient demographics for the entire population and comparing standard-dose vs reduced-dose groups the reduced-dose (31/32, 97%) vs the standard-dose cohort (32/37, 86%), P = .205. Steroid Benefit was seen in 95% (59/62) of the entire evaluable population. 29/29 patients in the reduced dose bevacizumab group had a steroid benefit, while 30/33 (91%) of the standard dose bevacizumab group achieved a steroid benefit (P = .241, Table S3 ).
Total population N (%)
Standard-dose bevacizumab N (%)
Reduced-dose bevacizumab N (%) P-value
| Age at diagnosis and time from diagnosis to bevacizumab start as predictive markers
31 patients were <50 at the time of diagnosis (mOS: 5.80 months), 57 patients were aged between 50-65 years (mOS: 5.80 months) and 30 patients were aged >65 (mOS: 6.07 months), common P-value: 0.173 ( Figure S4 ). 59 patients (50%) commenced bevacizumab within 12 months of histological GBM diagnosis (mOS: 5.3 months), 29 patients commenced bevacizumab between 12-18 months (mOS: 6.3 months), while 30 patients commenced bevacizumab at >18 months from histological GBM diagnosis (mOS: 6.8 months), common P-value: .665 ( Figure S5 ).
| Cost analysis
The total cost of bevacizumab administration across all patients for the duration of the study was €3,524,106.18 ($3,986,821.32). Among the 49 patients who received reduced-dose bevacizumab, total cost savings over the entire study period was €1,272,629.79 ($1,439,726.08). If reduceddose bevacizumab were applied to all 118 patients in the study, a cost reduction of €2,398,367.99 ($2,713,273.71) would be observed (Table S4 ).
| DISCUSSION
In this retrospective study, OS was statistically similar (5.97 vs 5.7 months; HR: 1.11, P-value: .584) with no clinically significant difference (Δ 0.27 months) among patients with progressive GBM who received standard-dose (N = 69) or reduced-dose (N = 49) bevacizumab. This homogenous WHO Grade IV patient population appear well balanced across all patient demographics assessed between the two dose cohorts, as demonstrated by univariate analysis (Tables 1 and Tables S1,S2 ). This suggests that reducing the bevacizumab dose-schedule has minimal or no impact on efficacy and that a reduced dose might be a preferable, cheaper option. Although this was not a prospective phase III trial, bevacizumab dose schedule was randomly determined based on the on-call system between three NeuroOncologists. We believe this limits the impact of selection bias on our conclusions. 10 mg/kg q2/52 was the standard-dose used in early and subsequent trials, where median OS results varied from 3.9-10 months (31-42 weeks), however bevacizumab was often administered in combination with Irinotecan or Lomustine. 9, [11] [12] [13] 19 Increasing evidence however suggests 10 mg/kg q2/52 may not be the optimum dose-schedule. Traditional dose-setting tools such as dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) are inadequate for monoclonal antibodies such as bevacizumab that target cell surface antigens, exhibit nonlinear pharmacokinetics due to receptor-mediated clearance and where activity can change due to disease severity or receptor loss following repeated dosing. [20] [21] [22] Studies investigating a lower dose bevacizumab regimen hypothesized this would offer similar benefits and lower toxicities. Lorgis 16 we noted that a higher number of treatments were administered to patients in the reduced-dose group (median 8 vs 6), which may reflect better tolerability as they had suggested, or a decreased propensity to "normalize" tumor vasculature, as has been suggested elsewhere. 14, 23 Given the cost of bevacizumab, these results have important implications for value in cancer care. Our cost analysis revealed that decreasing from standard (10 mg/kg) to reduced-dose (5 mg/kg) bevacizumab for 49 patients resulted in an estimated €1.3M saving. If all patients (N = 118) were treated with reduced-dose bevacizumab schedule, a €2.4M cost saving would be observed (Table S4) . While there are increased drug administration costs associated with an increased number of treatment cycles, this cost saving would undoubtedly represent better value.
Additionally, we identified a statistically significant OS benefit (HR 0.61, P = .027) for patients whose tumors had methylated MGMT promoters (Figure 2 ). To the best of our knowledge this has not previously been reported. This likely reflects favorable tumor biology and suggests that MGMT remains an important prognostic, but less important predictive, biomarker. 24 This retrospective study in a Western European predominantly Caucasian population was carried out in a national neuro-oncology centre with expertise in treating primary CNS tumors. Our results, therefore, may not be generalizable to other centres and this limitation should be taken into account when analysing our findings. Furthermore, due to the time span (2010-2017) and retrospective nature of the study, some patient records were not evaluable for steroid and clinical status analyses as they lacked reliable documentation or did not include adequate serial data and were therefore excluded. As a result, our steroid data and clinical status data sets and results reflect only a subset (64%) of the total population. Formal quality of life (QOL) indices and questionnaires were not applied routinely or consistently across our cohorts either and therefore were considered unreliable for valid retrospective analyses. These elements should be applied in future prospective studies in this field.
In conclusion, we feel two important points have been proven in this study. Firstly, reduced-dose bevacizumab has a similar OS to standard-dose bevacizumab monotherapy and is associated with a substantial cost saving. Secondly, MGMT methylation appears to convey a survival benefit even in the setting of bevacizumab treatment in progressive GBM. This study should help guide current clinical practice, future clinical studies and help improve value in cancer care.
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